Rebus

Ballard announces orders from Solaris for nearly 100 hydrogen fuel cell engines to power buses in Europe

Retrieved on: 
Tuesday, August 8, 2023

Ballard expects limited initial deliveries of the 96 fuel cell engines to start in late 2023, with most being delivered through 2024.

Key Points: 
  • Ballard expects limited initial deliveries of the 96 fuel cell engines to start in late 2023, with most being delivered through 2024.
  • The purchases orders include the largest single order to date that Ballard has received from Solaris – an order for 52 fuel cell engines that will power Solaris Urbino hydrogen buses for deployment by public transport operator Rebus Regionalbus Rostock, based in Güstrow, Germany.
  • In addition to the order for Güstrow-bound buses, Ballard has received orders from Solaris for an additional 44 fuel cell engines that will power Solaris buses in European cities.
  • These orders will add to the more than 110 fuel cell buses that Solaris has deployed with customers in Europe to date.

VertoTrade Officially Launches as the Premier Decentralized Exchange on Rebuschain

Retrieved on: 
Monday, April 17, 2023

Furthermore, VertoTrade is entirely decentralized, allowing users to trade directly from their non-custodial wallets, maintaining 100% ownership of their assets.

Key Points: 
  • Furthermore, VertoTrade is entirely decentralized, allowing users to trade directly from their non-custodial wallets, maintaining 100% ownership of their assets.
  • The VertoTrade platform will be powered by the $VERTO token, which will have a total supply of 600M tokens.
  • VertoTrade is an Automated Market Maker (AMM) exchange designed to offer a comprehensive suite of features that cater to the needs of both new and experienced traders.
  • As more projects build on Rebuschain, VertoTrade will be the go-to platform to interact with assets from those projects.

London Based Jewelry Atelier, Rebus, Honors Traditional Goldsmithing Techniques with Hand Engraved Cufflinks

Retrieved on: 
Thursday, June 30, 2022

NEW YORK, June 30, 2022 /PRNewswire-PRWeb/ -- Since the 18th century, cufflinks have been a staple in men's formal wear, aesthetically and functionally. Hatton Garden-based Rebus elevates the style, using the sophistication of classic cufflinks and melding them with client vision. A team of craftsmen and women from their in-house workshop use long-established methods and tools to lovingly craft exclusive, one-of-a-kind pieces that are cherished and passed down for generations. Each pair of cufflinks is individually polished and hand engraved by a master goldsmith in England, giving a personalized touch to each design. Unique and character-building, Rebus cufflinks add a dashing addition to a man's accessories. The perfect gift for him is the experience of making one's own heirloom cufflinks with the Rebus workshop, virtually or in-person.

Key Points: 
  • NEW YORK, June 30, 2022 /PRNewswire-PRWeb/ -- Since the 18th century, cufflinks have been a staple in men's formal wear, aesthetically and functionally.
  • Hatton Garden-based Rebus elevates the style, using the sophistication of classic cufflinks and melding them with client vision.
  • Each pair of cufflinks is individually polished and hand engraved by a master goldsmith in England, giving a personalized touch to each design.
  • The Rebus team is made up of award-winning hand engravers and goldsmiths, all with a heartfelt commitment to beautiful engraving using traditional hand tools.

Rebus Biosystems Partners with ROSALIND to Co-Develop Spatial Omics Software

Retrieved on: 
Wednesday, June 8, 2022

Rebus Biosystems Inc , (Rebus Bio, Rebus), an Illumina Ventures-backed life science technology company creating revolutionary tools to advance spatial omics research, announced today it is partnering with Rosalind, Inc. to co-develop new spatial omics software.

Key Points: 
  • Rebus Biosystems Inc , (Rebus Bio, Rebus), an Illumina Ventures-backed life science technology company creating revolutionary tools to advance spatial omics research, announced today it is partnering with Rosalind, Inc. to co-develop new spatial omics software.
  • The technology will democratize data from single cell spatial analyses from the Rebus Esper system, making important spatial omics insights accessible to the broader research community.
  • The new software being developed by Rebus and Rosalind will combine the power of the Rebus Esper spatial multi-omics capabilities with the highly interactive and intuitive interface of ROSALIND.
  • Rebus Biosystems is a venture-backed Silicon Valley-based life science technology company creating revolutionary tools to enable spatial omics research without compromise.

Rebus Biosystems Expands Scientific Advisory Board with Key Appointments

Retrieved on: 
Thursday, March 17, 2022

Rebus Biosystems Inc , (Rebus Bio, Rebus), an Illumina Ventures-backed life science technology company creating revolutionary tools to advance spatial omics research, announced today that Arnold Kriegstein, M.D., PhD.

Key Points: 
  • Rebus Biosystems Inc , (Rebus Bio, Rebus), an Illumina Ventures-backed life science technology company creating revolutionary tools to advance spatial omics research, announced today that Arnold Kriegstein, M.D., PhD.
  • and Kun Zhang, PhD., have been appointed to the Companys Scientific Advisory Board (SAB).
  • Kriegstein and Zhang to our Scientific Advisory Board, said Paul Sargeant, Ph.D., chief executive officer of Rebus.
  • Rebus Biosystems provides all-inclusive assay kits to empower researchers with the resolution, scale and speed of the Rebus Esper for multiple applications.

New Publication in Science Leverages Rebus Esper Platform to Create Cell Atlas of Brain Vasculature

Retrieved on: 
Thursday, January 27, 2022

They compared these cells with samples from healthy adult brain blood vessels to determine which genes were being expressed in the differing samples.

Key Points: 
  • They compared these cells with samples from healthy adult brain blood vessels to determine which genes were being expressed in the differing samples.
  • Finally, they created a comprehensive cell atlas of the vascular system in the brain.
  • The study, titled A single-cell atlas of the normal and malformed human brain vasculature was published today in the January 27 issue of Science.
  • Rebus Biosystems provides all-inclusive assay kits to empower researchers with the resolution, scale and speed of the Rebus Esper for multiple applications.

Boardriders Selects Longbow Advantage to Drive Warehouse Visibility and Labor Planning

Retrieved on: 
Wednesday, December 15, 2021

Rebus is a unified supply chain visibility platform that provides real-time views into the warehouse for distribution teams who need access to make point-in-time decisions about their warehouse operations, labor management, and inventory.

Key Points: 
  • Rebus is a unified supply chain visibility platform that provides real-time views into the warehouse for distribution teams who need access to make point-in-time decisions about their warehouse operations, labor management, and inventory.
  • Rebus Warehouse Visibility is the only solution that provides real-time visibility into the heart of the supply chainthe warehouse.
  • "We are incredibly pleased for the opportunity to help Boardriders take its warehouse visibility to the next level, fine tune areas of the warehouse, and optimize labor management with unmatched visibility," said Alex Wakefield, CEO of Longbow Advantage.
  • Longbow is committed to providing exceptional experiences for distribution teams with unified, real-time visibility into warehouse operations and through expert end-to-end supply chain implementations and consulting.

Rebus Bio Continues Expansion of Industry-leading Spatial Omics Platform with Breakthrough High-Plex Technology

Retrieved on: 
Wednesday, December 8, 2021

Running the Enhanced Electric FISH (EEL) assay on the Esper platform enables spatial transcriptomics with single-cell resolution and has the potential to scale to more than 5,000 genes.

Key Points: 
  • Running the Enhanced Electric FISH (EEL) assay on the Esper platform enables spatial transcriptomics with single-cell resolution and has the potential to scale to more than 5,000 genes.
  • This will more effectively yield improved, simple spatial workflows for a variety of sample types and disease areas on one platform.
  • Rebus Biosystems is a venture-backed Silicon Valley-based life science technology company creating revolutionary tools to enable spatial omics research without compromise.
  • The company's first instrument, the Rebus Esper, is a fully integrated, automated spatial omics platform that delivers quantitative single molecule, single-cell data with subcellular resolution.

Rebus Biosystems Strengthens Management Team with Executive Appointments in Operations and Product Development

Retrieved on: 
Tuesday, November 16, 2021

Truong will serve as Vice President, Operations and Ramakrishnan will hold the position of Senior Vice President, Product Development.

Key Points: 
  • Truong will serve as Vice President, Operations and Ramakrishnan will hold the position of Senior Vice President, Product Development.
  • Viet and Ramesh are joining Rebus at an opportune time where their combined Operations and Product Development backgrounds will be integral to our future growth and success, said Paul Sargeant, Ph.D., CEO of Rebus Biosystems.
  • Dr. Ramakrishnan brings more than 25 years of product development experience in the life science industry to his new role Senior Vice President, Product Development at Rebus.
  • I am pleased to become part of the Rebus team and their accomplished and talented professionals leading product development, said Ramesh Ramakrishnan, Ph.D., Senior Vice President, Product Development, Rebus Biosystems.

Rebus Biosystems Appoints World-leading Researchers to Scientific Advisory Board

Retrieved on: 
Tuesday, November 2, 2021

Rebus Biosystems Inc. , (Rebus Bio, Rebus), an Illumina Ventures-backed life science technology company creating revolutionary tools to advance spatial omics research, today announced that Drs.

Key Points: 
  • Rebus Biosystems Inc. , (Rebus Bio, Rebus), an Illumina Ventures-backed life science technology company creating revolutionary tools to advance spatial omics research, today announced that Drs.
  • Arul Chinnaiyan, MD, PhD, and Sten Linnarsson, PhD, have been appointed to the Companys Scientific Advisory Board (SAB).
  • Were very proud to have Arul and Sten join the Rebus team, said Paul Sargeant, PhD, CEO of Rebus Biosystems.
  • Rebus Biosystems provides all-inclusive assay kits to empower researchers with the resolution, scale and speed of the Rebus Esper for multiple applications.